西妥昔单抗联合化疗治疗中晚期食管癌的临床观察

摘要
图/表
参考文献(21)
相关文章 (15)

全文: PDF (418 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨西妥昔单抗联合化疗治疗中晚期食管癌的临床观察。方法选取浙江中医药大学附属同德医院2013年2月～2016年5月收治的中晚期食管癌患者80例为研究对象，采用随机数字表法将患者分为对照组（n = 40）和研究组（n = 40），对照组给予氟尿嘧啶联合顺铂（FP）化疗治疗，研究组在此基础上联合西妥昔单抗治疗，比较两组患者临床疗效、肿瘤标志物水平、生存质量、生存率以及不良反应。结果研究组治疗4个周期后临床总有效率高于对照组（P ＜ 0.05）。两组患者治疗4个周期后鳞状细胞癌抗原（SCC）、癌胚抗原（CEA）均降低，且研究组低于对照组（P ＜ 0.05）。两组治疗4个周期后欧洲癌症研究组织生存质量测定（EORTC QLQ-C30）量表评分均升高，且研究组高于对照组（P ＜ 0.05）。研究组随访12、18、24个月后生存率高于对照组，但组间比较差异无统计学意义（P ＞ 0.05）。两组治疗期间不良反应发生率比较，差异无统计学意义（P ＞ 0.05）。结论西妥昔单抗联合化疗治疗中晚期食管癌，效果确切，可有效改善肿瘤标志物水平，改善患者生存质量，且不增加不良反应发生率，临床应用价值较高。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘志军何忠良陈国兴何雪明

关键词 ：西妥昔单抗, 化疗, 中晚期, 食管癌, 临床疗效

Abstract：Objective To investigate the clinical observation of Cetuximab combined with Chemotherapy in the treatment of middle and advanced esophageal cancer. Methods Eighty patients with advanced esophageal cancer admitted to Tongde Hospital Affiliated to Zhejiang Chinese Medical University from February 2013 to May 2016 were selected as research objects. Patients were divided into control group (n = 40) and study group (n = 40) by random number table method. The control group was given Fluorouracil combined with cisplatin (FP) chemotherapy, and the study group was combined with Cetuximab on the basis of the conttol group. The clinical efficacy, tumor marker level, quality of life, survival rate and adverse reactions of the two groups were compared. Results The total clinical response rate of the study group was higher than that of the control group (P ＜ 0.05). After 4 cycles of treatment, SCC and CEA were decreased in both groups, and the study group were lower than those in the control group (P ＜ 0.05). EORTC QLQ-C30 scale score was increased in both groups after 4 cycles of treatment, and the group was higher than the control group (P ＜ 0.05). The survival rate of the study group was higher than that of the control group after follow-up of 12, 18 and 24 months, but there were no statistically significant difference between the two groups (P ＞ 0.05). There was no statistically significant difference between the two groups in the incidence of adverse reactions during treatment (P ＞ 0.05). Conclusion Cetuximab combined with Chemotherapy in the treatment of advanced esophageal cancer has a definite effect, can effectively improve the level of tumor markers, improve the quality of life of patients, without increasing the incidence of adverse reactions, and has a high clinical application value.

Key words： Cetuximab Chemotherapy Middle and advanced stage Esophageal cancer Clinical efficacy

基金资助:浙江省医药卫生科技计划项目（2019322843）。

通讯作者: 何忠良（1964.12-），男，硕士，主任医师；研究方向：心胸外科。

引用本文:

刘志军何忠良陈国兴何雪明. 西妥昔单抗联合化疗治疗中晚期食管癌的临床观察[J]. 中国医药导报, 2019, 16(23): 156-159.
LIU Zhijun HE Zhongliang CHEN Guoxing HE Xueming. Clinical observation of Cetuximab combined with Chemotherapy in the treatment of middle and advanced esophageal cancer. 中国医药导报, 2019, 16(23): 156-159.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2019/V16/I23/156

[1] 汪文杰.人类表皮生长因子受体2在食管鳞癌组织中的表达及对预后的影响[D].郑州：郑州大学，2017.
[2] 伍义文.汉防己甲素对食管癌细胞凋亡相关蛋白Survivin、Caspase-3表达的影响[D].广州：南方医科大学，2013.
[3] Loeser H，Kraemer M，Gebauer F，et al. The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma [J]. Oncoimmunology，2019，8（5）：e1581546.
[4] Subramanian S，Sridharan N，Balasundaram V，et al. Effectiveness and tolerability of nimotuzumab in unresectable，locally advanced/metastaticesophageal cancer：Indian hospital-based retrospective evidence [J]. South Asian J Cancer，2019，8（2）：112-115.
[5] 蔡中立，丁春萍，冀胜辉，等.钼对食管癌细胞ECA-109化疗增敏及食管癌干细胞p75NTR的抑制[J].中国组织工程研究，2015，19（50）：8084-8089.
[6] 陈永东，王远东，李晓宁，等.西妥昔单抗联合化疗在中晚期食管癌术后辅助治疗中的应用效果观察[J].实用医学杂志，2014，30（17）：2862-2863.
[7] 周际昌.实用肿瘤内科学[M].人民卫生出版社，1999.
[8] 张娴，魏玲，吴栋文，等.欧洲癌症治疗研究组织生活质量量表-BR23浅析[J].山西医药杂志，2014，43（17）：2031-2033.
[9] 张百红，岳红云.实体瘤疗效评价标准简介[J].国际肿瘤学杂志，2016，43（11）：845-847.
[10] 蔡庆勇.CCR7基因对食管鳞状细胞癌新生血管的作用及机制研究[D].重庆：第三军医大学，2016.
[11] 曾海燕，袁双虎，孟雪等.食管癌放疗穿孔防治研究进展[J].中华肿瘤防治杂志，2017，24（7）：501-506.
[12] Kasagi Y，Saeki H，Ando K，et al. Clinical results of preoperative CDDP/5-FU chemotherapy followed by surgery for patients with clinical stage II/III thoracic esophageal cancer [J]. Fukuoka Igaku Zasshi，2013，104（12）：523-529.
[13] 赵骞，宁旭.TP方案同步放化疗对非手术局部晚期食管癌的疗效[J].贵州医科大学学报，2017，42（8）：952-956.
[14] 张金泽，刘俊峰，李海洋，等.pT1b～3N0M0期食管鳞状细胞癌辅助化疗对远期疗效的影响[J].中华外科杂志，2018，56（4）：289-293.
[15] 樊璠，白鸽，张建清，等.西妥昔单抗联合放化疗治疗食管癌的Meta分析[J].现代肿瘤医学，2016，24（13）：2073-2078.
[16] 贺春语，张见龙，刘如，等.西妥昔单抗对人食管癌EC9706细胞株的放射增敏作用及其机制[J].中华实验外科杂志，2016，33（3）：685-687.
[17] 王勐，张连民，赵晓亮，等.西妥昔单抗与盐酸埃克替尼联用可以克服表皮生长因子受体T790M突变非小细胞肺癌的继发耐药[J].中华肿瘤杂志，2014，36（9）：651-656.
[18] Osumi H，Yoshio T，Chin K，et al. Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer [J]. Gastric Cancer，2016，19（2）：625-630.
[19] Takaoka A，Ishikawa T，Sasaki M，et al. Two Cases of Rectal Cancer with Pelvic Local Recurrence Complicated with Sepsis after RectalCancer Surgery Successfully Treated with Radiation Therapy [J]. Gan To Kagaku Ryoho，2018，45（13）：2078-2080.
[20] 李瑾昱，焦顺昌，张国庆，等.表皮生长因子受体表达水平对西妥昔单抗及其介导的抗体依赖的细胞介导的细胞毒作用杀伤肺腺癌A549细胞的影响[J].中国医学科学院学报，2014，36（2）：164-167.
[21] Huang ZH，Ma XW，Zhang J，et al. Cetuximab for esophageal cancer：an updated meta-analysis of randomized controlled trials [J]. BMC Cancer，2018，18（1）：1170.